|
|
|
| The Application of Desogestrel and Ethinylestradiol Tablets in the treatment of Abnormal Uterine Bleeding in Perimenopause |
| SUN Xingxing, et al |
| The Affiliated Hospital of Jiangsu University, Jiangsu Changzhou 213002, China |
|
|
|
|
Abstract Objective: To investigate the abnormal uterine bleeding in perimenopausal patients, using the clinical effect of marvelon. Methods: 84 cases of abnormal uterine bleeding in the perimenopausal period were selected and divided into two groups randomly, 42 cases in each group. Mifepristone (1 times /d, 12.5mg each time) was used as the control group, and Desogestrel and Ethinylestradiol Tablets (2-3 /d, 3-4 tablets each time, 1 /d) was used as the observation group. The levels of sex hormones (follicle stimulating hormone (FSH), progesterone (P), estradiol (E2), luteinizing hormone (LH)), uterine volume and endometrial thickness, adverse reactions and therapeutic effects in two groups after 3 courses of treatment were observed. Results: The levels of FSH, P, E2 and LH in the observation group were significantly lower than those in the control group (P<0.05). The measurements of uterine volume and endometrium thickness in the observation group were less than those of the control group (P<0.05). The total effective rate of clinical treatment in the control group was 80.95%, and the total effective rate in the observation group was 92.86% (P<0.05). The adverse incidence rate of the control group was 7.14%, and the adverse incidence rate of the observation group was 19.05% (P<0.05). Conclusion: Compared with mifepristone in the treatment of abnormal uterine bleeding in perimenopausal period, Desogestrel and Ethinylestradiol Tablets has a more significant clinical effect, and improves the indicators and uterus of patients more obviously, but it is easy to cause acne and obesity, so we should pay attention to drug reactions.
|
|
|
|
|
|
[1] 陈卫东.妈富隆联合安宫黄体酮治疗青春期功能失调性子宫出血的临床效果[J].齐齐哈尔医学院学报,2016,32(33):4186~4188.
[2] 杨玉环.妈富隆与雌激素对青春期功能失调性子宫出血的疗效观察[J].实用妇科内分泌杂志(电子版),2016,2(1):27~28.
[3] 谢幸,苟文丽.妇产科学[M].北京:人民卫生出版社,2013.344.
[4] 程丽娟.妈富隆治疗围绝经期功能失调性子宫出血疗效观察[J].现代诊断与治疗,2015,25(21):4888~4889.
[5] 宋淑华,刘爱华.妈富隆治疗围绝经期功能失调性子宫出血的疗效观察[J].包头医学院学报,2015,321(3):69~70.
[6] El Behery MM,Saleh HS,Ibrahiem MA,et al.Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia[J].Reprod Sci,2015,22(3):329~334.
[7] 梁栋,洪顺家,李维茹.妈富隆对绝经过渡期功能失调性子宫出血患者血清性激素水平的影响[J].中国妇幼保健,2014,28(2):265~267.
[8] Park DS,Kim ML,Song T,et al.Clinical experiences of the levonorgestrel-releasing intrauterine system in patients with large symptomatic adenomyosis[J].Taiwan Obstet Gynecol,2015,54(4):412~415.
[9] Abu Hashim H, Ghayaty E, El Rakhawy M. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials[J]. Am Obstet Gynecol,2015,213(4):469~478.
[10] Paradisi R, Rossi S, Scifo MC, et al. Recurrence of endometrial polyps[J]. Gynecol Obstet Invest,2014,78(1):26~32. |
|
|
|
2018, Vol. 24 
